Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cassava Sciences, Inc.

< Previous 1 2 Next >
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Reports Q2 2025 Financials Results and Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Reports Q1 2025 Financials Results, Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Licenses Simufilam Method of Treatment Patent
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Provides a Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences to Hold Corporate Update on November 25th
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Reports Q3 2024 Financial and Operating Results
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Resolves SEC Investigation
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Names Rick Barry as Chief Executive Officer
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Announces Expansion of Open-Label Extension Trials
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers MDXG SAVA SRPT
Cassava Sciences Issues Statement on Former Science Advisor
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.